Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo. Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia in adults, adolescents and children two years of age and older with diabetes […]
Contract Services
GM Instruments, Sensonics partner on nasal and oral measurement devices
GM Instruments announced today that it partnered with Sensonics to develop devices for the quantitative assessment of nasal and oral function. The companies tout the first-of-its-kind partnership as a bringing together of sensory and engineering expertise for evaluating and treating nasal and oral diseases. Additionally, the companies expect the partnership to establish the influences of […]
Lyra inks $135M partnership to expand chronic rhinosinusitis treatment in Asia
Lyra Therapeutics (NSDQ:LYRA) announced today that it entered into a strategic partnership with LianBio for its LYR-210 treatment for chronic rhinosinusitis. Watertown, Mass.–based Lyra, which develops the LYR-210 therapeutic to be locally delivered by its proprietary XTreo platform, could receive up to $135 million in total payments through the strategic partnership and exclusive license agreement […]
West Pharmaceutical Services beats Street in Q1, raises guidance
West Pharmaceutical Services (NYSE:WST) posted Street-beating first-quarter financial results and raised its full-year guidance for 2021. The Exton, Pa.-based company posted profits of $151.2 million, or $1.99 per share, on sales of $670.7 million for the three months ended March 31, 2021, more than doubling its bottom-line on sales growth of 36.5%. Adjusted to exclude […]
SciNeuro inks licenscing deal with Eli Lilly for targeted antibody therapies
SciNeuro Pharmaceuticals announced today that it entered into an exclusive licensing agreement with Eli Lilly for antibody therapies. Under the agreement, Shanghai-based SciNeuro obtained an exclusive license to develop and commercialize alpha-synuclein targeted antibodies developed by Lilly within Greater China, which includes mainland China, Hong Kong, Macau and Taiwan, according to a news release. The […]
Pear Therapeutics inks multiple agreements to expand digital therapeutic platform
Pear Therapeutics announced today that it entered into multiple agreements to bolster its prescription digital therapeutics (PDT) platform. Boston-based Pear Therapeutics’ agreements are set to add to its library of digital biomarkers, machine learning algorithms, sensor-based technologies and digital therapeutics, according to a news release. The agreements have been struck with technology companies including Empatica, […]
Seelos, Aptar sign deal for Bidose system to deliver ketamine candidate
Seelos Therapeutics (NSDQ:SEEL) announced today that it partnered with AptarGroup (NYSE:ATR) for the Bidose liquid system device. The agreement includes the co-exclusive use and supply of Aptar Pharma’s Bidose device to deliver Seelos’ intranasal ketamine product candidate, SLS-002, for treating suicidality, depression and post-traumatic stress disorder (PTSD). Under the agreement, Seelos garners certain rights to […]
BrightInsight raises $101M for its pre-built digital health platform
BrightInsight announced today that it’s raised $101 million in a Series C round led by VC firm General Catalyst. The money will go toward more hiring and further accelerating the work BrightInsight is conducting with customers to support their digital health product launches. The San Jose, Calif.–based company offers a turnkey digital health platform for […]
Diomics, Bonne Santé Group enter strategic alliance
Diomics and Bonne Santé Group announced today that they entered into a strategic alliance to develop a line of Diocare products. San Diego-based Diomics and Miami-based Bonne Santé Group, which operated through its Bonne Santé Natural Manufacturing division, entered the agreement in an effor tto develop, launch and distribute the Diocare products formulated to address […]
Eyenovia partners with Eversana to commercialize pupil dilation agent
Eyenovia (NSDQ:EYEN) announced today that it partnered with Eversana to help commercialize MydCombi if it earns U.S. approval. MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience. The FDA earlier this month accepted Eyenovia’s New Drug […]
